Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VANCOUVER, WASH. AND NEW YORK, DEC. 16, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE UPCOMING 44TH ANNUAL J.P.

ABSCI TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

INHIBITING PROLACTIN RECEPTOR (PRLR) SIGNALING WITH THE ABS-201 ANTI-PRLR ANTIBODY PROMOTES HUMAN HAIR FOLLICLE GROWTHEX VIVO

ABSCI REPORTS NEW HUMAN EX VIVO DATA DEMONSTRATING THAT ABS-201 STIMULATES HAIR GROWTH AND REGENERATES STEM CELL NICHE TO POTENTIALLY REVERSE FOLLICLE MINIATURIZATION

PARTNERSHIP AIMS TO DESTIGMATIZE ANDROGENETIC ALOPECIA AND HIGHLIGHT THE NEED FOR NEW THERAPEUTIC OPTIONS THAT ADDRESS THE ROOT CAUSE OF DISEASE

ABSCI AND U.S. SOCCER LEGEND LANDON DONOVAN PARTNER TO CHAMPION THE PATIENT VOICE IN HAIR LOSS RESEARCH

STUDY TO EVALUATE SAFETY AND EFFICACY OF NOVEL ANTI-PRLR ANTIBODY; INTERIM DATA ANTICIPATED IN THE SECOND HALF OF 2026 TRIAL DESIGN LEVERAGES OPERATIONAL SYNERGIES TO ENABLE ACCELERATED REGISTRATIONAL TRIALS FOR ANDROGENETIC ALOPECIA (AGA) AND PHASE 2 FOR ENDOMETRIOSIS KOL SEMINAR SCHEDULED FOR DECEMBER 11 TO DISCUSS NEW HUMAN EX VIVO DATA, CLINICAL TRIAL DESIGN, AND MARKET OPPORTUNITY IN AGA VANCOUVER, WASH. AND NEW YORK, DEC. 04, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THAT THE FIRST HEALTHY VOLUNTEERS HAVE BEEN DOSED IN THE PHASE 1/2A HEADLINE STUDY EVALUATING ABS-201, AN INVESTIGATIONAL ANTI-PROLACTIN RECEPTOR (PRLR) ANTIBODY ENGINEERED WITH ABSCI'S GENERATIVE AI PLATFORM.

ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE TRIAL OF AI-DESIGNED ANTIBODY ABS-201 FOR ANDROGENETIC ALOPECIA

REPORTED INTERIM RESULTS FOR PHASE 1 TRIAL FOR ABS-101 (ANTI-TL1A) ON TRACK TO INITIATE PH1/2A TRIAL FOR ABS-201 (ANTI-PRLR FOR ANDROGENETIC ALOPECIA) IN DECEMBER; HOSTING KOL SEMINAR ON DECEMBER 11 EXPANDING ABS-201 STRATEGY TO PURSUE ENDOMETRIOSIS AS ADDITIONAL INDICATION; ANTICIPATE INITIATION OF PHASE 2 CLINICAL TRIAL IN THE FOURTH QUARTER OF 2026 CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES SUFFICIENT TO FUND OPERATIONS INTO THE FIRST HALF OF 2028 VANCOUVER, WASH. AND NEW YORK, NOV. 12, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025.

ABSCI REPORTS BUSINESS UPDATES AND THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

VANCOUVER, WASH. AND NEW YORK, OCT. 29, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE THIRD QUARTER 2025 AFTER MARKET CLOSE ON WEDNESDAY, NOVEMBER 12, 2025.

ABSCI TO REPORT BUSINESS UPDATES AND THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON NOVEMBER 12, 2025

VANCOUVER, WASH. AND NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

ABSCI TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WEBINAR ON DECEMBER 11 TO FEATURE LEADING KOLS IN DERMATOLOGY AND HAIR LOSS ALONGSIDE ABSCI LEADERSHIP PHASE 1/2A TRIAL NOW EXPECTED TO BEGIN IN DECEMBER 2025, AHEAD OF PRIOR GUIDANCE VANCOUVER, WASH. AND NEW YORK, OCT. 15, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL HOST A VIRTUAL SEMINAR ON DECEMBER 11, 2025 AT 10:00AM ET FOCUSED ON THE COMPANY'S ABS-201 (ANTI-PRLR) PROGRAM FOR ANDROGENETIC ALOPECIA.

ABSCI TO HOST KOL SEMINAR ON ABS-201 ANDROGENETIC ALOPECIA PROGRAM ON DECEMBER 11, 2025; ANNOUNCES ACCELERATED INITIATION OF PHASE 1/2A TRIAL

PERFORMANCE AND SCALABILITY OF ORACLE CLOUD INFRASTRUCTURE AI INFRASTRUCTURE ENABLES ABSCI TO ACCELERATE BIOLOGICS DESIGN CYCLES AND REDUCE COSTS PERFORMANCE AND SCALABILITY OF ORACLE CLOUD INFRASTRUCTURE AI INFRASTRUCTURE ENABLES ABSCI TO ACCELERATE BIOLOGICS DESIGN CYCLES AND REDUCE COSTS

ABSCI ACCELERATES AI-DRIVEN DRUG DISCOVERY WITH ORACLE AND AMD

WORLD-RENOWNED EXPERTS WILL GUIDE THE CLINICAL DEVELOPMENT OF ABS-201, A THERAPEUTIC ANTIBODY ENTERING CLINICAL TRIALS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA. WORLD-RENOWNED EXPERTS WILL GUIDE THE CLINICAL DEVELOPMENT OF ABS-201, A THERAPEUTIC ANTIBODY ENTERING CLINICAL TRIALS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA.

Absci Corporation

ABSI

Price

Financial Reports

No items found.

Press Releases

Absci Corporation

ABSI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABSI